Skip to content
Study details
Enrolling now

Cannabidiol for Reduction of Brain Neuroinflammation

Massachusetts General Hospital
NCT IDNCT05066308ClinicalTrials.gov data as of Apr 2026
Phase

Phase 2

Target enrollment

80

Study length

about 4.9 years

Ages

18–75

Locations

1 site in MA

What this study is about

Researchers are testing whether cannabidiol (CBD), a treatment, can reduce brain inflammation in adults with chronic pain and/or depression. The trial will last 1806 days.

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Placebo
  • 2.Take CBD

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
Standard

How treatment is administered

Treatment Assignment
Randomized & Blinded

You may get a placebo/standard care, and you won't know which.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Drug classes

cannabinoid

Endpoints

Secondary: Change in Clinical Pain Ratings, Change in Depressive Symptoms, Change in Pain Bothersomeness, Correlation Between Reductions in Limbic [11C]PBR28 PET Signal and Reductions in Depressive Symptoms, Correlation Between Reductions in Thalamic [11C]PBR28 PET Signal and Reductions in Clinical Pain Ratings, Patient Global Impression of Change

Body systems

Psychiatry / Mental Health